PDCD1 and nonpapillary renal cell carcinoma: Although numerous researchers have developed many biomarkers to predict the survival time of patients with ccRCC, they have not been able to predict the survival time of patients receiving immunotherapy because the patients included did not receive anti-PD-1 treatment [55,56,57].